Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To evaluate the efficacy (combined morphologic and flow remissions) of a combination of
fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL.
Secondary Objective:
- To evaluate remission duration and survival.